Dáil Éireann Debate, Tuesday - 24 January 2017
498. Deputy Mick Barry asked the Minister for Health if a person (details supplied) will be permitted to access a cannabis based medicine to potentially assist the reduction in the amount and severity of seizures they suffer from. [3172/17]
View answerCannabidiol (CBD) is derived from cannabis. However, since it does not have psychoactive properties it is not controlled under the Misuse of Drugs Acts.
While I am aware that CBD oil is sometimes marketed as a nutritional or dietary supplement, it should be noted that it is not authorised as a medicinal product in Ireland. Under European and Irish legislation, before a medicine can be placed on the Irish market, the manufacturer must seek an authorisation from the Health Products Regulatory Authority (HPRA) or, in the case of certain medicinal products, the European Medicines Agency. A determination on an application for authorisation of a medicinal product is based on a rigorous scientific assessment of the application against the criteria of safety, quality, efficacy, legal and regulatory requirements. I have no role in the process of authorising medicinal products.
No application has been received from any company for any products containing CBD. The HPRA are open to receiving such applications.
Elsewhere products containing CBD are undergoing clinical trials for the treatment of a number of medical conditions, including severe, intractable (treatment-resistant) epilepsy. There is no prohibition on an Irish registered doctor recommending CBD for a patient under his/her care if they deem that treatment option to be clinically appropriate for their patient.
